The deal would vault the combined company to 7th-largest biosimilar player globally, with direct implications for biologic access in dermatology.
Under the terms of the agreement, Sun Pharma will pay $14.00 per share for all outstanding Organon stock, representing a premium for stockholders of the New Jersey-based company. The transaction has been approved by the boards of both companies and is expected to close in early 2027, pending regulatory approvals and a vote by Organon stockholders.
For dermatologists and advanced practice clinicians, the deal carries particular relevance given Sun Pharma's existing prominence in the specialty. The company's global innovative medicines portfolio — which already accounts for approximately 20% of its total revenue — is anchored in dermatology, ophthalmology, and oncodermatology. The acquisition of Organon would layer in a substantial biosimilar business, vaulting the combined entity to 7th-largest biosimilar player globally.
Organon, which was spun off from Merck in 2021, markets more than 70 products across women's health and general medicines in over 140 countries. Its biosimilars portfolio has been a growing component of that general medicines segment, and with biologics increasingly central to dermatologic care — from psoriasis to atopic dermatitis to hidradenitis suppurativa — the expansion into biosimilars carries direct implications for the specialty.2
"This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives," said Dilip Shanghvi, executive chairman of Sun Pharma. "Organon's portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the 2 organizations together can create a stronger and more diversified platform."
If completed as planned, the combined company would rank among the top 25 global pharmaceutical firms with projected combined revenue of approximately $12.4 billion. Sun Pharma would gain a top-3 position in global women's health and a commercial presence in 150 countries, with 18 markets each generating more than $100 million in annual revenue.
The deal is also framed as a catalyst for Sun Pharma's innovative medicines strategy, which would represent 27% of combined revenue post-close. Kirti Ganorkar, managing director of Sun Pharma, emphasized plans for disciplined integration and business continuity. "Together, we will become a partner of choice for acquiring and launching new products," Ganorkar said, adding that the companies see meaningful revenue synergies on the horizon.
Both companies have emphasized business continuity as an immediate priority. Prescribers should expect no near-term changes to product availability or support.
Sun Pharma's core innovative medicines portfolio is anchored in dermatology and oncodermatology. Adding Organon's biosimilar infrastructure could affect long-term access and pricing for biologic therapies across the specialty.
Organon reported $6.2 billion in revenue and adjusted EBITDA of $1.9 billion for the year ended December 31, 2025. The company carried $8.6 billion in debt at year-end, offset in part by a $574 million cash balance. Organon recently completed the divestiture of an undisclosed product for $440 million upfront, proceeds that will contribute to its cash position ahead of closing. Sun Pharma plans to fund the acquisition through a combination of internal cash resources and committed bank financing, with post-transaction net debt-to-EBITDA projected at 2.3x.
Organon executive chair Carrie Cox described the transaction as the outcome of a thorough strategic review. "Our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Cox said. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."
The near-term impact on prescribers is expected to be minimal — both companies have emphasized business continuity as an immediate priority. Longer term, the expanded biosimilar platform could affect access and pricing dynamics for biologic therapies across dermatology and beyond, particularly in international markets where Organon has deep commercial infrastructure.
The deal remains subject to customary regulatory review. If approved on schedule, the combined company would begin operations in early 2027.
References
